Cadence Capital Management’s Medifast MED Stock Holding History

Cadence Capital Management’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-32,010	Closed	-$2.99M	–	682
2018 Q1	$2.99M	Buy	32,010 +1,621	+5%	+$121K	0.19%	121
2017 Q4	$2.12M	Buy	30,389 +2,180	+8%	+$145K	0.13%	176
2017 Q3	$1.68M	Buy	28,209 +1,365	+5%	+$67.9K	0.1%	240
2017 Q2	$1.11M	Buy	26,844 +1,462	+6%	+$63.6K	0.08%	337
2017 Q1	$1.13M	Buy	25,382 +1,074	+4%	+$46.2K	0.08%	311
2016 Q4	$1.01M	Sell	24,308 -927	-4%	-$37.3K	0.07%	352
2016 Q3	$954K	Buy	+25,235	New	+$905K	0.07%	325
2014 Q1	–	Sell	-37,405	Closed	-$977K	–	631
2013 Q4	$977K	Hold	37,405	–	–	0.04%	441
2013 Q3	$1.01M	Sell	37,405 -7,635	-17%	-$204K	0.03%	433
2013 Q2	$1.16M	Buy	+45,040	New	+$1.18M	0.05%	278

Other funds holding MED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Cadence Capital Management's MED Position: Q2 2018 in Review

Cadence Capital Management sold out of Medifast (MED) in Q2 2018, closing a stake of 32,010 shares — an estimated $2.99M sold.

Cadence Capital Management first reported a position in MED in Q2 2013 and held it in 10 quarters. The position peaked at $2.99M in Q1 2018. 258 funds tracked by Wall St. Rank hold MED as of Q2 2018.

Cadence Capital Management reported no remaining Medifast position as of Q2 2018 after selling out during the quarter.
Cadence Capital Management sold 32,010 Medifast shares in Q2 2018, an estimated $2.99M.
Cadence Capital Management first reported a position in Medifast in Q2 2013 and held it in 10 quarters.
Cadence Capital Management's Medifast position peaked at $2.99M in Q1 2018.
258 funds tracked by Wall St. Rank held Medifast as of Q2 2018.

Based on Cadence Capital Management's 13F filing for Q2 2018, filed 9 Aug 2018.